Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. 2001

S P Mönig, and S E Baldus, and J K Hennecken, and D B Spiecker, and G Grass, and P M Schneider, and J Thiele, and H P Dienes, and A H Hölscher
Department of Surgery, University of Cologne, Joseph-Stelzmann-Strasse 9, 50924 Cologne, Germany. moenigst@aol.com

OBJECTIVE One important step in tumour invasion is the penetration of the basement membrane. Matrix metalloproteinases (MMPs) play a key role in the migration of normal and malignant cells through the basement membrane. The aim of this study was to investigate correlations between matrix metalloproteinase 2 (MMP-2) immunoreactivity and currently used classification systems and possible relationships between lymph node metastasis and MMP-2 expression. RESULTS This prospective study analysed specimens obtained from 114 gastric cancer patients (mean age 64 years; range 33-86 years) who underwent gastrectomy with extended lymphadenectomy. All specimens were categorized according to UICC classification, WHO classification, tumour differentiation, Laurén classification, Ming classification and Goseki classification. Formalin-fixed paraffin-embedded tumour specimens were stained using an avidin-biotin complex peroxidase assay. MMP-2 expression in the tumour epithelium was studied by immunohistochemistry with semiquantitative (score 0-3) evaluation. The MMP-2 staining pattern was positive (score 1-3) in 93 (81.6%) specimens and negative (score 0) in 21 (18.4%) samples. No significant correlations were found between MMP-2 expression and other variables such as age, tumour differentiation, WHO, Lauren, Goseki, and Ming classifications. In contrast, the intensity of MMP-2 staining in tumour cells correlated significantly with depth of tumour infiltration (T-stage), lymph node metastasis (N-stage), distant metastasis (M-stage), and UICC stage. CONCLUSIONS Expression of MMP-2 is strongly associated with tumour progression and lymph node metastasis in gastric cancer. Therefore MMP-2 staining may be clinically useful as predictor of tumour progression, especially for lymph node metastasis.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

S P Mönig, and S E Baldus, and J K Hennecken, and D B Spiecker, and G Grass, and P M Schneider, and J Thiele, and H P Dienes, and A H Hölscher
September 2007, Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery,
S P Mönig, and S E Baldus, and J K Hennecken, and D B Spiecker, and G Grass, and P M Schneider, and J Thiele, and H P Dienes, and A H Hölscher
March 2000, Histopathology,
S P Mönig, and S E Baldus, and J K Hennecken, and D B Spiecker, and G Grass, and P M Schneider, and J Thiele, and H P Dienes, and A H Hölscher
May 2002, Cancer research,
S P Mönig, and S E Baldus, and J K Hennecken, and D B Spiecker, and G Grass, and P M Schneider, and J Thiele, and H P Dienes, and A H Hölscher
May 2006, World journal of gastroenterology,
S P Mönig, and S E Baldus, and J K Hennecken, and D B Spiecker, and G Grass, and P M Schneider, and J Thiele, and H P Dienes, and A H Hölscher
January 2012, Journal of gastroenterology,
S P Mönig, and S E Baldus, and J K Hennecken, and D B Spiecker, and G Grass, and P M Schneider, and J Thiele, and H P Dienes, and A H Hölscher
January 2017, PloS one,
S P Mönig, and S E Baldus, and J K Hennecken, and D B Spiecker, and G Grass, and P M Schneider, and J Thiele, and H P Dienes, and A H Hölscher
June 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
S P Mönig, and S E Baldus, and J K Hennecken, and D B Spiecker, and G Grass, and P M Schneider, and J Thiele, and H P Dienes, and A H Hölscher
August 2013, Oncology letters,
S P Mönig, and S E Baldus, and J K Hennecken, and D B Spiecker, and G Grass, and P M Schneider, and J Thiele, and H P Dienes, and A H Hölscher
August 2014, Journal of molecular histology,
S P Mönig, and S E Baldus, and J K Hennecken, and D B Spiecker, and G Grass, and P M Schneider, and J Thiele, and H P Dienes, and A H Hölscher
January 1995, International journal of cancer,
Copied contents to your clipboard!